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Abstract The insulin receptor family consists of the homo-
logous tyrosine kinase receptors, insulin receptor (IR), insulin-
like growth factor 1 receptor (IGF1R) and insulin receptor-
related receptor. The three-dimensional structures of the tyrosine
kinase domain of the IR and the first three extracellular domains
(L1, Cys-rich and L2) of the IGF1R are known. Here we present
evidence that the connecting domain of the IR family is a member
of the fibronectin type III (FnIII) superfamily. Structure-based
alignment of FnIII domains reveals several key residues that are
also conserved in the sequence of the connecting domain. The
alignment of the connecting domain with FnIII domains is in
good agreement with secondary structure prediction. A model of
the connecting domain shows a hydrophobic core formed by the
conserved residues and is consistent with previously known
biochemical data. This suggests that the IR family contains three
FnIII domains in tandem in the extracellular juxtamembrane
region.
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1. Introduction
The insulin receptor family comprises the homologous in-
sulin receptor (IR), insulin-like growth factor 1 receptor
(IGF1R) and insulin receptor-related receptor (IRR). These
integral membrane glycoproteins are each synthesised as a
single polypeptide chain and then proteolytically processed
to produce two chains, K and L, which are linked by a disul-
phide bond. The active receptor is a dimer K2L2, bound by
two disulphide bonds [1]. The K-chain is extracellular, whereas
the L-chain consists of a short extracellular region, a single
transmembrane segment and an intracellular tyrosine kinase
domain involved in signal transduction. The ligand binding
regions are contained in the extracellular K-chain. Ligand
binding a⁄nity and speci¢city are central to receptor activa-
tion, regulation and function.
The extracellular region consists of six domains. The three-
dimensional (3D) structure of the ¢rst three domains, L1, Cys-
rich and L2, of the IGF1R has been de¢ned by X-ray analysis
[2,3], as well as the structure of the intracellular tyrosine ki-
nase domain of IR [4]. Little is known, however, about the
structure of the rest of the extracellular region, where three
other domains have been identi¢ed: a connecting domain (res-
idues 468^588) and two repeats of ¢bronectin type III do-
mains (FnIII) (residues 593^820 and 821^929; residue num-
bers are those of human IR throughout this paper) [5,6].
In spite of the extensive similarity in amino acid sequence,
domain structure and signalling mechanism between the re-
ceptors, the residues involved in ligand binding are di¡erent in
IR and IGF1R. A⁄nity labelling experiments and studies
with chimeric IRs indicate that at least three separate regions
in the K-chain of IR (residues 1^120, 459^524 and 713^718)
are involved in insulin binding [7,8]. More recent studies, us-
ing alanine scanning mutagenesis and analogue binding prop-
erties, have shown that the N-terminal 120 amino acids and
residues 704^715 of the K-chain play a major role [9,10],
although the fragment consisting of residues 1^462 of the
IGF1R does not bind ligand on its own [3].
The region of the connecting domain can be deleted without
seriously compromising insulin binding [10^12], but residues
450^601 appear to be a major immunogenic determinant for
inhibitory monoclonal antibodies as well as patients’ autoim-
mune anti-IR antibodies. Therefore, this region was called
‘major immunogenic region’ (MIR) [13]. A blunted tyrosine
autophosphorylation response in deletion studies of this re-
gion [11] suggests that it may be involved in the transmission
of the signal, after insulin interaction, to the tyrosine kinase.
Here we suggest that the connecting domain is another
FnIII repeat and that the IR family, therefore, has three con-
secutive FnIII domains. We call this novel FnIII domain
FnIII0, because the next two domains have already been des-
ignated FnIII1 and FnIII2.
2. Materials and methods
The PSI-Blast [14] search was performed on the NCBI WWW serv-
er. The secondary structure prediction with PHD [15^17] and Jpred
[18] was carried out on the EMBL and EBI WWW servers respec-
tively. Other secondary structure prediction programs Spetor [19,20]
and Predator [21,22] were run locally.
The list of FnIII domains with known structures was taken from
SCOP [23] and the structure-based alignment was obtained using
COMPARER [24,25] followed by manual adjustment. The sequences
of the connecting domains of the IR family were added by CLUS-
TALX [26]. The ¢nal alignment was manually adjusted.
Two known structures of FnIII domains were chosen as the tem-
plate for the modelling of IR and IGF1R connecting domain. These
were domain two of the growth hormone receptor (PDB code 3hhr)
and domain eight of ¢bronectin (PDB code 1fnf). The model was built
using MODELLER [27]. Evaluation of the model was carried out
with Verify 3D [28] and Procheck [29]. The cycle of realignment,
modelling and structure evaluation was repeated until no further im-
provements on the structure were observed. Similarly, the model of
the three-domain structure (FnIII0, FnIII1 and FnIII2) of IGF1R was
built with MODELLER using domains seven, eight and nine of ¢-
bronectin (PDB code 1fnf), domain two of neuroglian (PDB code
1cfb) and domain two of growth hormone receptor (PDB code 3hhr).
3. Results and discussion
The high degree of sequence similarity between IR, IGF1R
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Fig. 1. Sequence alignment of FnIII domains with the sequences of the connecting domains of the IR family. Structure-based alignment of
FnIII domains were generated with COMPARER [24,25] and formatted by JOY [40]. Aligned proteins are: 1fnf1, 1fnf2, 1fnf3 and 1fnf4: ¢bro-
nectin, domains seven, eight, nine and ten (PDB code 1fnf); 1ten: tenascin (PDB code 1ten); 1cfb1 and 1cfb2: neuroglian, domains one and
two (PDB code 1cfb); 1cto: granulocyte colony stimulating factor receptor (g-csf-r) (PDB code 1cto); 1ebp1 and 1ebp2: erythropoietin receptor
(epo-r) domains one and two (PDB code 1ebp); 3hhr1 and 3hhr2: growth hormone receptor (gh receptor) domains one and two (PDB code
3hhr); IGF1R_human: human IGF1R; (Swiss-Prot accession P08069); IGF1R_pig: pig IGF1R (Q29000; Q28951); IGF1R_rat: rat IGF1R
(P24062); IGF1R_mouse: mouse IGF1R (Q60751; Q62123); IGF1R_gallo: Gallus gallus IGF1R (TrEMBL P79773); IR_human: human IR
(P06213); IR_rat: rat IR (P15127; P9768); IR_mouse: mouse IR (P15208); IRR_human: human IRR (P14616); IRR_capvo: Cavia porcellus
IRR (P14617). Residue numbers are shown in parentheses. The bottom line of the alignment (Jpred) shows the secondary structure prediction
result by Jpred. E: L-strand; H: K-helix.
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and IRR indicated that all three will have similar structures.
In the following we will mainly discuss IR, but similar argu-
ments apply to the other members.
A PSI-Blast search [14] for the connecting domain of the
three proteins did not give any signi¢cant hit. We then ran
several secondary structure prediction programs, including
PHD [15^17], Spetor [19,20], Predator [21,22] and Jpred
[18], all of which strongly indicated that there are seven L-
strands in the domain. The two highest scoring proteins pre-
dicted by Threader [30] were also both L-proteins; these were
immunoglobulin (Ig) and ¢bronectin. After a careful exami-
nation of the structure-based alignments, the sequence of the
connecting domain showed signi¢cantly higher compatibility
with the ¢bronectin domain than with the Ig fold (see below).
FnIII domains all adopt a conserved L-sandwich with seven
strands (see Fig. 2C), despite the low sequence identity (be-
tween 8 and 20%) among the members of the family. Thus,
structure-based alignment is essential to characterise the se-
quence conservation pattern within this family. We used
COMPARER [24,25], in conjunction with some manual ad-
justments, to obtain a structure-based alignment of FnIII do-
mains (Fig. 1).
Residues highly conserved in the FnIII domain are: Pro in
the A-strand, Trp in the B-strand, Tyr in the C-strand, Tyr in
the F-strand and Leu six residues N-terminal of this Tyr,
which is located in the E-F loop [31]. Most of these residues
are buried in the structure and form a hydrophobic core.
There are other conserved buried hydrophobic residues in
the FnIII fold, suggesting that they might have an important
role in stabilising the hydrophobic core of the domain. These
residues are located two and four residues N-terminal of the
conserved Trp in the B-strand, two residues C-terminal of the
conserved Tyr in the C-strand and two and four residues C-
terminal of the conserved Tyr in the F-strand (Fig. 1).
We added the sequences of the connecting domain to the
structure-based alignment of FnIII. It can be seen that most
of the key residues are also conserved in the connecting do-
main of the IR family sequences (Figs. 1 and 2A), except for
Pro in the A-strand. Trp (residue 489) in the B-strand is con-
served. Phe-503, instead of Tyr, is in the C-strand. This is a
conservative substitution and Phe is also present in some of
the FnIII domains with known structure. Tyr-562 in the F-
strand is conserved, as well as Leu-556 in the loop between
strands F and E. Other buried hydrophobic residues impor-
tant in the FnIII fold are present in the sequence of the con-
necting domain, e.g. Leu-487 in the B-strand, Leu-505 in the
C-strand, Ile-564 and Val-566 in the F-strand.
The alignment is also in good agreement with the secondary
structure prediction. As an example, the secondary structure
prediction by Jpred [18] is shown in Fig. 1. Note that our
input to the secondary structure prediction programs was ei-
ther a single sequence or a multiple alignment of the connect-
ing domains of the IR family. No program detected any other
sequence similarity and therefore, information that would
have been gained from the multiple alignment of sequences
with those of FnIII domains was never used in these se-
condary structure predictions.
Although both FnIII and Ig domains adopt a seven-
stranded L-sandwich, key residues are not conserved between
them and they are regarded as di¡erent superfamilies [23]. A
careful examination of alignments of the connecting domain
with several Ig domains was carried out. Alignments of the
sequences of the connecting domain with C1 set -constant
immunoglobulin-, C1 set -constant non immunoglobulin-, V
set -variable non immunoglobulin-, I set and the C2 set, were
made and analysed using the structure-based alignments in the
HOMSTRAD database [32]. The conserved residues of Ig, as
well as the sequence separation of the main residues in the
characteristic ‘pin’ structure of Ig-like molecules [33], were not
present in the connecting domain.
We built a model of the IR and IGF1R connecting domain.
Two known structures that show the highest sequence identity
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with the target sequences were chosen as the template for
modelling. These structures were domain two of the growth
hormone receptor (Protein Data Bank (PDB [34,35]) code,
3hhr) and domain eight of ¢bronectin (PDB code 1fnf). Their
sequence identities with the target were 25 and 20% respec-
tively.
The model is shown in Fig. 2. In the model, all the con-
served residues point inwards, making a tightly packed hydro-
phobic core. Evaluation with Verify 3D [28] produced all pos-
itive scores. Evaluation of the stereo-chemical quality of the
model with Procheck [29] showed that only a few residues
(8.4% for IR and 1.9% for IGF1R) are in disallowed regions
in the Ramachandran plot.
Eight monoclonal antibodies that inhibit insulin binding to
its receptor were found to bind to an epitope in residues 450^
601, within FnIII0 of the human IR [13]. The ¢nding that
none recognises the mouse IR helped narrow the epitopes
recognised by these antibodies. In this region all the di¡er-
ences in amino acid sequence between mouse and human re-
ceptors (except for a single substitution of Phe by Tyr in
residue 476) are located between residues 535 and 548. These
13 amino acids are therefore likely to constitute an epitope
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Fig. 2. A: Backbone representation of the model of the FnIII0 domain of IR. Shown in black are the side chains of the conserved residues in
the FnIII fold. Figure generated by RASMOL [41]. B: Cartoon representation of the models of the FnIII0 domain of IR and IGF1R. In the
model of IR, Cys-524 forming the K-K disulphide bond is labelled. Residues in the principal immunogenic loop are shown in black. Residues,
conserved in the IR family and not in the FnIII family, are shown in ball-and-stick representation. Figure generated with MOLSCRIPT [42]
and RASTER3D [43,44]. C: Schematic representation of the hydrogen bond patterns in the model of the FnIII0 domain of IR. Only residues
located in a L-strand are shown in a circle (buried) or in a square box (exposed). Figure generated by HERA [45].
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recognised by the eight antibodies [13]. This is consistent with
our model, where these residues are located in the loop be-
tween strands CP and E (Fig. 2B).
Residues conserved among the members of the IR family
should play structural and/or functional roles. Structural key
residues should be also conserved in the FnIII family, assum-
ing that they adopt a similar fold. Thus, the ones conserved
only within the IR family, but not the FnIII family, are likely
to be involved in the activity. These residues, displayed as
ball-and-stick in Fig. 2B, are indeed mainly polar and located
on the surface. Furthermore, many of these residues cluster in
two regions. First, the loops C-CP and E-F contain highly
conserved residues (Glu-517 to Gly-525 and Lys-557 to Ala-
563 respectively), which cluster on the same face of the L-
sandwich. The loop C-CP includes Cys-524 that forms the
disulphide bridge between the protomers and therefore this
cluster is likely to be involved in protomer-protomer interac-
tions. This is consistent with the putative location of the epit-
ope on the opposite side of the fold (Fig. 2B). The identi¢ca-
tion of the protomer-protomer interaction region can help in
the design of mutations, e.g. introducing another Cys to make
the dimer more stable. The second cluster is found on the loop
B-C (Arg-498 to Leu-500) and this might be involved in the
interactions with the ¢rst three domains of the extracellular
region.
There are some functional similarities between the connect-
ing domain and other FnIII domains. FnIII domains often
exist proximal to the membrane [36,37], suggesting that they
may play a role in dimerisation, e.g. binding to similar FnIII
modules [38]. That is also the case of the connecting domain
in the IR family where the K-K disulphide bridge (residue 524
in IR) plays an important role in dimerisation.
Our ¢nding that the connecting domain belongs to the
FnIII superfamily, indicates that the extracellular region of
the IR family contains three FnIII domains in the extracellu-
lar juxtamembrane region. A model of the three FnIII do-
mains of IGF1R is shown in Fig. 3. Although there is not
much information about the relative orientation of the three
domains, a single disulphide bond between FnIII1 and FnIII2
appears to be a strong constraint. Fig. 3 shows that the three
domains can be arranged linearly, an arrangement of FnIII
domains that has been previously observed in the crystal
structure of ¢bronectin [39].
4. Conclusions
Several lines of evidence strongly suggest that the connect-
ing domain in the IR family is a FnIII domain.
Very little is known about the last three domains of the
extracellular region and a better knowledge might be useful
in understanding the mechanism of how IGFI, IGFII and
insulin transmit signals through the receptor to produce their
metabolic and mitogenic e¡ect. Identi¢cation of particular
residues and knowledge of their possible position in the 3D
structure may help design further mutagenesis studies, such as
making an additional disulphide bond to stabilise the K2L2
dimer. Our model of the 3D structure provides detailed hy-
pothesis about domain linkers and this may assist crystallisa-
tion studies. The model may also help engineer a peptide to
use in enzyme-linked immunoassays for screening for anti-
receptor antibodies.
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